CLNN vs. GLSI, LFCR, ABEO, ALIM, RIGL, VERU, SGMT, CNTX, RNAC, and PRQR
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Greenwich LifeSciences (GLSI), Lifecore Biomedical (LFCR), Abeona Therapeutics (ABEO), Alimera Sciences (ALIM), Rigel Pharmaceuticals (RIGL), Veru (VERU), Sagimet Biosciences (SGMT), Context Therapeutics (CNTX), Cartesian Therapeutics (RNAC), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical preparations" industry.
Clene (NASDAQ:CLNN) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.
23.3% of Clene shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 25.1% of Clene shares are owned by insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Clene received 54 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 75.95% of users gave Clene an outperform vote while only 37.50% of users gave Greenwich LifeSciences an outperform vote.
Greenwich LifeSciences has lower revenue, but higher earnings than Clene. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Clene had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 5 mentions for Clene and 4 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.06 beat Clene's score of 0.61 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
Clene has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.
Greenwich LifeSciences has a net margin of 0.00% compared to Clene's net margin of -7,873.23%. Greenwich LifeSciences' return on equity of -117.99% beat Clene's return on equity.
Clene currently has a consensus price target of $6.50, suggesting a potential upside of 1,875.68%. Greenwich LifeSciences has a consensus price target of $36.00, suggesting a potential upside of 142.75%. Given Clene's higher probable upside, equities research analysts clearly believe Clene is more favorable than Greenwich LifeSciences.
Summary
Clene beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
